Literature DB >> 9684789

Factor XII does not initiate prekallikrein activation on endothelial cells.

R Røjkjaer1, A A Hasan, G Motta, I Schousboe, A H Schmaier.   

Abstract

It is well known that on artificial surfaces, binding and autoactivation of factor XII (FXII) is the initiating event of plasma prekallikrein (PK) activation. We performed investigations to examine whether this mechanism was true for FXII activation on endothelial cells (HUVEC). Activation of PK on HUVEC required an optimal substrate and Zn2+ concentration, the latter of which varied with the buffer's carrier protein. Maximal PK activation required the addition of 250 microM or 10 microM Zn2+ to buffers containing bovine serum albumin (BSA) or gelatin, respectively. However, the actual free Zn2+ concentration in these buffers was the same at 8 microM. In both BSA- and gelatin-containing buffers and using two different chromogenic substrates for FXII, no autoactivation of FXII on HUVEC was seen when incubated for up to 60 min. Rather, initiation of FXII enzymatic activity required the presence of PK. FXII activation after PK activation contributed to the extent of measured enzymatic activity, but its role was secondary because treatment with corn trypsin inhibitor or a neutralizing antibody to FXIIa did not abolish the measured enzymatic activity. They also reduced the activity to the level seen with PK activation alone. Alternatively, soybean trypsin inhibitor abolished the proteolytic activity associated with PK and FXII activation on HUVEC. Further, only normal human and FXII-deficient plasmas, not PK-deficient plasma, had the ability to generate proteolytic activity when incubated over endothelial cells. In a purified system, maximal PK activation was measured after a 10-15 min incubation depending upon the concentration of reactants. When FXII was added with the PK, maximal activation occurred within 7.5-10 min. In normal human or FXII-deficient plasmas, but not in PK-deficient plasma, maximal activation was seen in 4 min. These data indicate that on HUVEC, unlike artificial surfaces, PK activation when bound to HK is the initiating activation event in this system. FXII activation is secondary to PK activation and contributes to the extent of measured enzymatic activity. These data challenge the accepted dogmas of "contact activation" and suggest that on biologic membranes a new notion as to how this system is activated needs to be considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684789

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  The plasma kallikrein-kinin system counterbalances the renin-angiotensin system.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 3.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

4.  Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

Authors:  Kusumam Joseph; Baby G Tholanikunnel; Allen P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 5.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

Review 6.  The many faces of the contact pathway and their role in thrombosis.

Authors:  Rebecca S Woodruff; Bruce Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

7.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin.

Authors:  Zia Shariat-Madar; Fakhri Mahdi; Mark Warnock; Jonathon W Homeister; Sujata Srikanth; Yelena Krijanovski; Laine J Murphey; Ayad A Jaffa; Alvin H Schmaier
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

Review 9.  The elusive physiologic role of Factor XII.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 10.  Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system.

Authors:  Alvin H Schmaier
Journal:  Int Immunopharmacol       Date:  2007-09-05       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.